in this issue
Regions :: North America
Roche to buy US biotech firm InterMune for $8.3 billion
8:38 AM MDT | August 25, 2014 | Natasha Alperowicz
Roche (Basel) said today that it has agreed to acquire InterMune (Brisbane, CA), a biotech company focused on R&D and commercializing therapies in pulmonology and orphan fibrotic diseases, for $8.3 billion. The offer represents a premium of 38% to InterMune’s closing price on 22 August and a premium of 63% to InterMune’s unaffected closing price on 12 August. Both companies' boards have approved the agreement. The transaction is expected to close this year. Roche, under the terms of the agreement, will commence a tender offer by 29 August...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee